244 related articles for article (PubMed ID: 20368559)
1. Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: adherence companion study 60104.
Partridge AH; Archer L; Kornblith AB; Gralow J; Grenier D; Perez E; Wolff AC; Wang X; Kastrissios H; Berry D; Hudis C; Winer E; Muss H
J Clin Oncol; 2010 May; 28(14):2418-22. PubMed ID: 20368559
[TBL] [Abstract][Full Text] [Related]
2. Quality of life of older patients with early-stage breast cancer receiving adjuvant chemotherapy: a companion study to cancer and leukemia group B 49907.
Kornblith AB; Lan L; Archer L; Partridge A; Kimmick G; Hudis C; Winer E; Casey R; Bennett S; Cohen HJ; Muss HB
J Clin Oncol; 2011 Mar; 29(8):1022-8. PubMed ID: 21300923
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant chemotherapy in older women with early-stage breast cancer.
Muss HB; Berry DA; Cirrincione CT; Theodoulou M; Mauer AM; Kornblith AB; Partridge AH; Dressler LG; Cohen HJ; Becker HP; Kartcheske PA; Wheeler JD; Perez EA; Wolff AC; Gralow JR; Burstein HJ; Mahmood AA; Magrinat G; Parker BA; Hart RD; Grenier D; Norton L; Hudis CA; Winer EP;
N Engl J Med; 2009 May; 360(20):2055-65. PubMed ID: 19439741
[TBL] [Abstract][Full Text] [Related]
4. Persistence, adherence, and toxicity with oral CMF in older women with early-stage breast cancer (Adherence Companion Study 60104 for CALGB 49907).
Ruddy KJ; Pitcher BN; Archer LE; Cohen HJ; Winer EP; Hudis CA; Muss HB; Partridge AH
Ann Oncol; 2012 Dec; 23(12):3075-3081. PubMed ID: 22767584
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER2-negative breast cancer.
Babacan T; Efe O; Hasirci AS; Demirci F; Buyukhatipoglu H; Balakan O; Sarici F; Kertmen N; Esin E; Akin S; Ates O; Aksoy S; Sever AR; Altundag K
Tumori; 2015; 101(4):418-23. PubMed ID: 25953439
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial.
Joensuu H; Kellokumpu-Lehtinen PL; Huovinen R; Jukkola-Vuorinen A; Tanner M; Kokko R; Ahlgren J; Auvinen P; Paija O; Helle L; Villman K; Nyandoto P; Nilsson G; Pajunen M; Asola R; Poikonen P; Leinonen M; Kataja V; Bono P; Lindman H
J Clin Oncol; 2012 Jan; 30(1):11-8. PubMed ID: 22105826
[TBL] [Abstract][Full Text] [Related]
7. Capecitabine in elderly patients with metastatic breast cancer.
De Sanctis R; Quadrini S; Longo F; Lapadula V; Restuccia R; Del Signore E; De Filippis L; Stumbo L; Gori B; Bianco V; Speranza I; Basile ML; Di Seri M
Tumori; 2012; 98(3):303-7. PubMed ID: 22825504
[TBL] [Abstract][Full Text] [Related]
8. Comorbidity, chemotherapy toxicity, and outcomes among older women receiving adjuvant chemotherapy for breast cancer on a clinical trial: CALGB 49907 and CALGB 361004 (alliance).
Klepin HD; Pitcher BN; Ballman KV; Kornblith AB; Hurria A; Winer EP; Hudis C; Cohen HJ; Muss HB; Kimmick GG
J Oncol Pract; 2014 Sep; 10(5):e285-92. PubMed ID: 25074878
[TBL] [Abstract][Full Text] [Related]
9. Fixed-dose capecitabine is feasible: results from a pharmacokinetic and pharmacogenetic study in metastatic breast cancer.
Rudek MA; Connolly RM; Hoskins JM; Garrett-Mayer E; Jeter SC; Armstrong DK; Fetting JH; Stearns V; Wright LA; Zhao M; Watkins SP; McLeod HL; Davidson NE; Wolff AC
Breast Cancer Res Treat; 2013 May; 139(1):135-43. PubMed ID: 23588952
[TBL] [Abstract][Full Text] [Related]
10. Safety profile and activity of lower capecitabine dose in patients with metastatic breast cancer.
Rossi D; Alessandroni P; Catalano V; Giordani P; Fedeli SL; Fedeli A; Baldelli AM; Casadei V; Ceccolini M; Catalano G
Clin Breast Cancer; 2007 Dec; 7(11):857-60. PubMed ID: 18269775
[TBL] [Abstract][Full Text] [Related]
11. Toxicity profile and efficacy of oral capecitabine as adjuvant chemotherapy for Chinese patients with Stage III colon cancer.
Law CC; Fu YT; Chau KK; Choy TS; So PF; Wong KH
Dis Colon Rectum; 2007 Dec; 50(12):2180-7. PubMed ID: 17963003
[TBL] [Abstract][Full Text] [Related]
12. Capecitabine non-adherence: exploration of magnitude, nature and contributing factors.
Bhattacharya D; Easthall C; Willoughby KA; Small M; Watson S
J Oncol Pharm Pract; 2012 Sep; 18(3):333-42. PubMed ID: 22298660
[TBL] [Abstract][Full Text] [Related]
13. Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial.
Muss HB; Polley MC; Berry DA; Liu H; Cirrincione CT; Theodoulou M; Mauer AM; Kornblith AB; Partridge AH; Dressler LG; Cohen HJ; Kartcheske PA; Perez EA; Wolff AC; Gralow JR; Burstein HJ; Mahmood AA; Sutton LM; Magrinat G; Parker BA; Hart RD; Grenier D; Hurria A; Jatoi A; Norton L; Hudis CA; Winer EP; Carey L
J Clin Oncol; 2019 Sep; 37(26):2338-2348. PubMed ID: 31339827
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial.
von Minckwitz G; Kümmel S; Vogel P; Hanusch C; Eidtmann H; Hilfrich J; Gerber B; Huober J; Costa SD; Jackisch C; Loibl S; Mehta K; Kaufmann M;
J Natl Cancer Inst; 2008 Apr; 100(8):542-51. PubMed ID: 18398097
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of preoperative capecitabine in women with operable hormone receptor positive breast cancer.
Tolaney SM; Jeong J; Guo H; Brock J; Morganstern D; Come SE; Golshan M; Bellon J; Winer EP; Krop IE
Cancer Med; 2014 Apr; 3(2):293-9. PubMed ID: 24464780
[TBL] [Abstract][Full Text] [Related]
16. [Oral capecitabine as postoperative adjuvant chemotherapy in stage III colon cancer patients].
Yamaguchi T; Fukuda M; Yasui H; Okazaki S; Kubo K; Tanaka M; Une Y; Setoguchi Y; Hanada K; Moriyama S; Tani M; Murakami T; Okuchi Y; Ogiso S; Hata H; Sakata S; Otani T; Yamato T; Ikai I
Gan To Kagaku Ryoho; 2012 Mar; 39(3):389-93. PubMed ID: 22421765
[TBL] [Abstract][Full Text] [Related]
17. [Adjuvant chemotherapy in older women with breast cancer. CALGB Study (The Cancer and Leukemia Group B Study)].
Mallmann P; Nitschmann S
Internist (Berl); 2010 Jul; 51(7):923-4. PubMed ID: 20544172
[No Abstract] [Full Text] [Related]
18. Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women.
Bajetta E; Procopio G; Celio L; Gattinoni L; Della Torre S; Mariani L; Catena L; Ricotta R; Longarini R; Zilembo N; Buzzoni R
J Clin Oncol; 2005 Apr; 23(10):2155-61. PubMed ID: 15710946
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer.
Gajria D; Gonzalez J; Feigin K; Patil S; Chen C; Theodoulou M; Drullinsky P; D'Andrea G; Lake D; Norton L; Hudis CA; Traina TA
Breast Cancer Res Treat; 2012 Jan; 131(1):111-6. PubMed ID: 21898114
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of 4-weekly capecitabine monotherapy in advanced/metastatic breast cancer.
Kusama M; Nomizu T; Aogi K; Yoshimoto M; Horikoshi N; Tabei T; Noguchi S; Miura S; Yoshimura N; Kimura M; Toyama K; Shin E
Breast Cancer; 2010 Oct; 17(4):233-40. PubMed ID: 19633909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
